The abstract is read at the publisher; the summary is JClub's.
RMC-7977 monotherapy resistance in NRAS-mutated melanoma preclinical models emerges via Ppia (CYPA) or Map2k1 (MEK1) mutations, limiting durable RAS(ON) pathway inhibition.
- Why it matters: NRAS-mutated melanoma lacks effective pathway-targeted second-line options after immunotherapy failure, and resistance mechanisms to RAS(ON) multiselective inhibitors are needed to guide better regimens.
- What they did: The study tested RMC-7977 and daraxonrasib in NRAS-mutated melanoma cell lines and preclinical melanoma models, then analyzed resistance after RMC-7977 exposure and reviewed two daraxonrasib clinical case studies.
- The result: Resistance to RMC-7977 is linked to mutational silencing of CYPA expression or MEK1 activation, while daraxonrasib showed antitumor activity in one patient but progressive disease in another with baseline NRAS and MAP2K1 mutations.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.